Welcome to CDC stacks | Pre-exposure prophylaxis for prevention of HIV - 23202 | Stephen B. Thacker CDC Library collection
Stacks Logo
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.
 
 
Help
Clear All Simple Search
Advanced Search
Pre-exposure prophylaxis for prevention of HIV
  • Published Date:
    May 20, 2014
  • Source:
    Public health grand rounds ; 2014 April 22
  • Language:
    English
Filetype[PDF-1.47 MB]


Details:
  • Corporate Authors:
    Centers for Disease Control and Prevention (U.S.). Office of the Associate Director for Communication. ; National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (U.S.). Division of HIV/AIDS Prevention
. ;
  • Description:
    HIV pre-exposure prophylaxis : preclinical research in animal models [PDF version of the PowerPoint presentation by Walid Heneine, p. 2-15] -- Evolving evidence from clinical trials of HIV pre-exposure prophylaxis [PDF version of the PowerPoint presentation by Melanie Thompson, p. 16-31] -- Program and policy challenges for delivery of PrEP [PDF version of the PowerPoint presentation by Dawn K. Smith, p. 32-56].

    An estimated 50,000 individuals become infected with the human immunodeficiency virus (HIV) in the United States annually. A new prevention strategy, Pre-exposure Prophylaxis (PrEP), is intended for high-risk populations to reduce their risk of becoming infected with HIV. PrEP includes daily medication and routine follow-up. When used consistently, PrEP is shown to reduce the risk of HIV infection. If delivered effectively and used in combination with other proven prevention methods, PrEP may play a significant role in helping to address the HIV epidemic in the United States.

    Presented by: Walid Heneine, PhD, 
Surveillance, Antiretroviral Prophylaxis and Drug Resistance Team Lead
, Division of HIV/AIDS Prevention, 
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, CDC [
“HIV Pre-exposure Prophylaxis (PrEP) Preclinical Research in Animal Models”]; Melanie Thompson, MD
, Founder and Principal Investigator, 
AIDS Research Consortium of Atlanta
 [“Evolving Evidence from Clinical Trials of HIV Pre-Exposure Prophylaxis”]; Dawn Smith, MD, MS, MPH, 
Biomedical Interventions Activity Lead, Prevention with Negatives Team
, Division of HIV/AIDS Prevention, 
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, CDC
 [“Program and Policy Challenges for Delivery of PrEP”].

    Facilitated by: John Iskander, MD, MPH, Scientific Director, Public Health Grand Rounds; 
Phoebe Thorpe, MD, MPH, Deputy Scientific Director, Public Health Grand Rounds; 
Susan Laird, MSN, RN, Communications Manager, Public Health Grand Rounds.

  • Document Type:
  • Supporting Files:
    No Additional Files
No Related Documents.
You May Also Like: